author-photo

Heather L. McArthur

Cedars-Sinai Medical Center
Memorial Sloan Kettering Cancer Center

159

Papers

2571

Citations

Citation Trend

Filter By

Papers (115) Sort By

Journal Conference Others

ALEXANDRA/IMpassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in patients with early-stage triple-negative breast cancer.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.

2021 Current Treatment Options in Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Abstract PS17-07: Impact of chemotherapy (chemo) on t-cell maturation and clonal proliferation in early-stage and metastatic breast cancer

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
94 Effects of chemoimmunotherapy on the peripheral blood: insights from immune monitoring of a phase Ib trial of pembrolizumab and paclitaxel or capecitabine for triple-negative breast cancer (TNBC)

2021 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Advances in Combining Radiation and Immunotherapy in Breast Cancer

2021 Clinical Breast Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Abstract OT1-01-04: A randomized phase 2 study of peri-operative ipilimumab, nivolumab and cryoablation versus standard care in women with residual, early stage/resectable, triple negative breast cancer after standard-of-care neoadjuvant chemotherapy

2020 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Pembrolizumab for Early Triple-Negative Breast Cancer

2020 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (428)
Abstract OT2-04-03: Nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2- primary breast cancer: CheckMate 7FL

2020 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
Abstract OT1-08-06: International, phase 3 trial: Balixafortide (a CXCR4 antagonist) + eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer (FORTRESS) international, phase 3 trial: Balixafortide (a CXCR4 antagonist) + eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer (FORTRESS)

2020 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)